Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/ajd.14029 | DOI Listing |
Nanomedicine
November 2024
Department of Oral Medicine, School of Dentistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil; Núcleo de Terapias Nanotecnológicas (NTnano), Faculdade de Farmácia da Universidade Federal do Rio Grande do Sul, Brazil; Experimental Research Center, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil. Electronic address:
Actinic cheilitis (AC) is a lip disorder, with no standard treatment. Imiquimod (IMIQ) is an immunomodulator that treat precancerous lesions; however, its commercial form causes severe adverse effects. This study aimed to assess IMQ release from a chitosan hydrogel containing 0.
View Article and Find Full Text PDFBackground: The incidence of keratinocyte carcinomas (KCs), comprising basal and squamous cell carcinomas, is rising in the United States. Chemoprevention is one modality by which patients can reduce the incidence of KCs.
Methods: We performed a retrospective review of 327 patients who employed a combination of imiquimod 5% cream, 5-fluorouracil 2% solution, and tretinoin 0.
Australas J Dermatol
August 2023
Department of Dermatology, Hospital das Clínicas of São Paulo University, São Paulo, Brazil.
Int J Mol Sci
March 2023
Department of Medicine, McGill University, Montreal, QC H4A 3J1, Canada.
Actinic keratosis (AK) is among the most commonly diagnosed skin diseases with potentially life-threatening repercussions if left untreated. Usage of pharmacologic agents represents one of many therapeutic strategies that can be used to help manage these lesions. Ongoing research into these compounds continues to change our clinical understanding as to which agents most benefit particular patient populations.
View Article and Find Full Text PDFMater Today Bio
March 2022
School of Biomedical Sciences, Hunan University, Changsha, 410082, China.
Melanoma is a highly aggressive tumor located in the skin, with limited traditional therapies. In order to reduce the side effects caused by traditional administration method and amplify the killing effect of immune system against tumor cells, an in situ injectable hydrogel drug delivery system is developed for the first time which co-delivers doxorubicin (Dox) and imiquimod (R837) for the synergistic therapy of melanoma. The mechanical properties and stability of the hydrogel are characterized and the optimal doses of hydrogel and drugs are also identified.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!